Filter By Category
Archives
Share on -
AZELIRAGON
Generic Name: AZELIRAGON
ABSTRACT -
Azeliragon, also known as TTP488 or PF-04494700, is a small-molecule antagonist of the receptor for advanced glycation end products (RAGE). It has been studied in neurodegenerative and oncology-related research settings because RAGE signaling can contribute to inflammation, cellular stress, and tumour biology. It is not an established routine clinical therapy. Molecular formula: C₃₂H₃₈ClN₃O₂; molecular weight: 532.13 g/mol. Development/regulatory status: Investigational.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- No approved routine dosing schedule is established.
- Any dosing must follow a controlled clinical-trial protocol or specialist research plan.
- Dose selection depends on indication, age, hepatic function, concomitant medicines, and monitoring requirements.
- Do not self-administer or use outside approved research conditions.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Headache, dizziness, fatigue, or sleep disturbance
- Nausea, diarrhoea, abdominal discomfort, or reduced appetite
- Possible neuropsychiatric or cognitive-symptom changes in neurologic studies
- Laboratory abnormalities, including hepatic or metabolic changes
- Rash or hypersensitivity reactions
ALLERGIC REACTIONS -
Hypersensitivity to azeliragon or related compounds/products may occur. Symptoms may include:
- Infusion reaction or injection-site reaction where applicable
- Rash or urticaria
- Bronchospasm or breathing difficulty
- Facial, lip, tongue, or throat swelling
- Anaphylaxis
Important: Patients who develop an allergic reaction to azeliragon should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
- CYP-modifying drugs may alter exposure depending on metabolic pathway.
- CNS-active medicines may complicate neurologic safety assessment.
- Anticancer, anti-inflammatory, or investigational medicines require protocol-specific review.
- Patients should inform clinicians about all prescription, non-prescription, herbal, vaccine, and supplement use.
PREAUTIONS–
- Monitor neurologic status, hepatic parameters, and study-specific biomarkers as required.
- Use caution in significant liver disease, pregnancy, lactation, or severe systemic illness.
- Clinical benefit has not been established for routine use.
WARNINGS –
- Investigational drug: safety and efficacy remain under evaluation.
- Seek urgent care for severe allergic reaction, confusion, severe neurologic change, or serious hepatic symptoms.
- Keep out of reach of children.
Share on -
. Developed by